REVIEW ARTICLE

Contemporary approaches for identifying individual risk for periodontitis

Kenneth S. Kornman

Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA

Correspondence
Kenneth S. Kornman
Email: kenkornman@gmail.com

1 | WHY DO WE NEED TO INDIVIDUALIZE PERIODONTAL CARE?

Beginning in the late 1960s and extending through to the mid-1980s, several impressive clinical studies successfully simplified the causation of gingivitis and periodontitis to establish a primary role for bacterial accumulations on the teeth.[1-4] These early studies focused on initiation and reversal of gingivitis and demonstrated that the basic concept of a critical role for bacterial accumulations in periodontitis held up in dogs and appeared to be similar in populations such as tea workers in Sri Lanka[5-7] (Figure 1).

The key observations of a primary "cause" of gingivitis and periodontitis were followed by landmark longitudinal studies at the University of Michigan and the University of Gothenburg which established core principles in prevention and treatment of periodontitis.

The clinical experimental gingivitis studies in dental students and the experimental periodontitis studies in dogs strongly supported the general concept that bacterial accumulations on the teeth predictably led to gingivitis and, if untreated, progressed to periodontitis. The details of some of those studies and observations by many clinicians did not, however, support the concept that periodontitis was a simple linear relationship between bacterial accumulations and initiation and severity of periodontal disease. In spite of important gaps or contradictions in the evidence, the basic message was that we could predictably prevent and treat periodontitis by a combination of professional and patient-directed approaches to bacterial control. This was a major advance over the clinical concepts in the preceding period that resulted in conflicting approaches to the treatment of periodontitis and therefore less predictability in outcomes.

Unfortunately, we communicated to many dentists, hygienists, and patients an implicit extension of the new concept which suggested that the severity of periodontitis was a simple function of the magnitude of bacterial accumulations and the time of exposure. The unspoken corollary was that, given bacterial exposure, all individuals are equally susceptible to periodontitis, and if treated according to the proven principles from the longitudinal studies patients should respond in a predictable manner. If those concepts are correct, there is no clear value to stratifying a patient's risk for developing periodontitis or responding predictably to therapy.

> Key point: Evidence indicates that some individuals have greater risk for developing severe periodontitis and some do not respond predictably to standard treatment principles and maintenance care

Two major exceptions emerged but failed to dissuade clinicians from the concepts that everyone was equally susceptible and that everyone responded predictably to bacterial reduction therapy. The first exception was that among populations with no routine oral hygiene or professional dental care, most individuals developed only mild-to-localized moderate periodontitis.[8,9] The evidence that emerged from Sri Lanka over time indicated that despite extended exposure to substantial levels of bacteria and calculus on the teeth, only a small percentage of the population progressed to severe generalized periodontitis (Figure 2). The second exception was that among patients treated and maintained appropriately for advanced periodontitis, approximately 20%-25% continued to have disease progression and lose teeth,[10-12] and in some studies the disease progression during post-treatment maintenance care was associated with a small number of patient-level risk factors.[13-18] In addition, when adults, most of whom had participated in a standardized prevention program, were reevaluated after 10 years, 12.3% had lost multiple teeth because of periodontitis.[19] Recent studies of various designs appear to support earlier observations that, as a result of specific risk factors, some individuals have increased risk for severe periodontitis or for increased tooth loss or periodontitis progression.[20-25] Those studies and observations by many clinical periodontists are the primary rationale for individualizing risk for periodontitis.

FIGURE 1 Clinical research beginning in the 1960s led to a simple concept that rapidly became the dominant approach to prevent and treat gingivitis and periodontitis. The concept of bacterial plaque causation indicated that bacterial accumulations on the teeth, if not removed, initiated gingivitis which transitioned into periodontitis. The concept also suggested that continued exposure to bacteria over time would result in severe periodontitis


FIGURE 2 In studies of populations with minimal to no oral hygiene and substantial accumulations of bacteria on the teeth, most individuals developed mild periodontitis with localized moderate disease (green circles). A small group developed only mild periodontitis (blue circles), and a smaller group developed severe generalized periodontitis (red circles)[8,9]

Chronic complex diseases have variable presentations among affected patients and probably reflect the cumulative biological result of multiple factors that modify various components of the pathophysiology of the disease. Progressive tooth loss in a subset of patients treated for periodontitis is consistent with general concepts of the clinically meaningful role of individual differences in chronic diseases.

It is all about prevention of severe disease and complications? Leroy Hood's "P4 Medicine" has succinctly captured not only the overall vision of precision healthcare but emphasizes the critical role of prevention in precision medicine as an essential strategy for controlling chronic diseases.[26-28]

P4 medicine refers to programs that are:

- Personalized. Identifying on which disease path an individual is traveling as they age.
- Predictive. Identifying the disease path before an individual has developed a severe form of the disease or a major complication of the disease.
- Preventive. If one can intervene early at the predictive stage to modify the disease path there is an opportunity to extend the time until the individual develops sufficient disease severity and complications that there is compression of the individual's morbidity.
- Participatory. Many chronic diseases require patient participation to manage the disease successfully. Both prevention and treatment of periodontitis have a participatory element that is substantial, if not deterministic.

2 | WHAT DO WE MEAN BY "INDIVIDUAL RISK FOR PERIODONTITIS"?

Key point: *No facts about the future, only probabilities: Risk factors are how we estimate an individual's probability for future disease progression and response to standard therapies.*

Physicians and dentists have long used personalized approaches to manage their patients. The new era of precision medicine, often referred to as personalized, individualized, or stratified medicine, attempts to take advantage of molecular signatures or individual biomarkers combined with traditional risk factors to predict, more clearly, the course of one's disease or to guide choice of therapies.

Clinical use of precision medicine in oncology and rare disorders has greatly benefited patients through new drug development and better drug outcomes. For example, there are 2 main histologic subtypes of lung cancer which result in more than 150,000 deaths annually in the USA. In the past 10 years, subsets of non-small cell lung cancer have been identified based on mutations in key control points of multiple oncogenes. Of the 15 gene mutations identified to date in non-small cell lung cancer, drugs are currently approved for 8 .[29] At present, much of the focus in oncology is on matching the most appropriate drug to the causative mutation to stop disease progression and increase survival.

Use of precision medicine in oncology and rare diseases is a valuable model but it does not translate well for chronic diseases. In chronic diseases many of the strongest risk factors are environmental or acquired, such as smoking, diet, and obesity. The clinical features of a chronic disease phenotype are often the result of multiple biological pathways, each of which includes multiple genes and environmental factors that interact to regulate the pathway and ultimately the clinically observable expression of disease. For common chronic diseases, the biology is not as deterministic as in oncology and rare diseases, and the clinical expression is a probabilistic summation of the key pathways and their components.[30] The net result of the complexity of chronic disease is not 8 or 15 molecular subtypes of the disease that define treatment choice and response, as in non-small cell lung cancer, but rather a small number of clinical disease patterns that represent different trajectories over time and different responsiveness to standard interventions.

These are probably the result of many molecular subtypes that produce a few clinical disease patterns or phenotypes. Individuals with observed variations in clinical presentation, including age of onset, severity and extent of disease relative to age, and predictability of clinical response to conventional periodontal therapy, are unlikely to have differences in the actual pathophysiology of periodontitis in the periodontal tissues.

One might conclude that the functional changes in disease-associated tissues compared with health-associated tissues represent basically the same pathophysiology, regardless of the clinical differences among patients. If that is the case, then individuals with variations in clinical disease probably have the same disease. So, how do we explain the clinical differences we see? Based on current knowledge, individual differences in periodontitis progression appear to be explainable by biological modifiers, including: environmental factors (such as smoking); genetic variations that modify the immune-inflammatory response, alter wound healing, and influence bone and connective tissue remodeling; or an acquired disease (such as uncontrolled type 2 diabetes) that influences the individual's host response to bacterial challenge. The net result of one or more of these modifiers is a change in the rate of certain physiological pathways to influence the biological response to the bacterial challenge and reduction of that challenge.

The chronic diseases often display disease heterogeneity,[31,32] meaning that different pathways can lead to the same clinical phenotype (ie, "many to one"), and also genetic heterogeneity, in which one node in a pathway may lead to multiple diseases (ie, "one to many").[33] The latter phenomenon is evident when the same drug (eg, a tumor necrosis factor alpha blocker) shows clinical value in treatment of multiple complex chronic diseases.

To address the question of whether it is possible to identify individual risk for periodontitis, and perhaps more importantly if it is practical to do so, one must start with a set of risk factors that have been individually validated. As those risk factors probably influence one or more pathways, and we have multiple risk factors for a chronic disease such as severe chronic periodontitis, we must also have a mechanism to stratify patients using combinations of multiple risk factors (Box 1).

This involves a long and demanding process that requires 3 successive steps: step 1, identify/discover potential risk factors; step 2, clinically validate putative risk factors; and, step 3, demonstrate clinical utility attributable to the use of specific risk factors. As the primary objective of this paper is to address the clinical utility question of whether we can currently identify individual risk for periodontitis, it is out of its scope to review the evidence for discovery and clinical validation of potential risk factors. Fortunately, there are outstanding recent publications reviewing evidence for the major risk factors for periodontitis[34-39] and I will accept some of those factors as a starting point for this discussion of whether we can use existing clinical utility evidence, albeit very limited, to identify individual risk for periodontitis.

2.1 | Step 1: discovery of potential risk factors for periodontitis

Can we identify specific factors that are associated with patient differences in clinical signs of periodontitis, progression or severity, response to treatment, or systemic implications or periodontitis?

BOX 1   Identifying individual risk for periodontitis: start by explicitly defining the goal

1. Risk for this patient developing periodontitis?
2. Risk for this patient's periodontitis progressing to moderate to severe generalized periodontitis?
3. Risk for this patient having a less predictable response to standard periodontal therapies and maintenance care?
4. Risk for this patient's periodontitis having implications for systemic disease?

2.2 | Step 2: validity

Two types of medical test validity are important: analytical validity and clinical validity, discussed in further detail below.

- Analytical validity refers to the accuracy with which a trait can be identified and quantified. This can refer to clinical parameters and the reproducibility of measurements among different clinical examiners or the same examiner over time. It is important to assure and make publicly available the analytical validity of biochemical, genetic, and physiologic assays, whether single analyte assays or large multiplexed assays, for which very different levels of expertise may exist across multiple laboratories and diverse assay systems. Analytical validity also includes validation of data management systems that are used to collect, analyze, and report data. In recent years analytical validity problems with -omics data have been reported as a result of failure to assure analytical and clinical validity before clinical application of gene expression patterns.[40,41]

- Clinical validity describes the accuracy of a specific risk factor to influence a particular clinical outcome. For example, is there evidence that a specific risk factor changes the biology in a manner that is relevant to severity/progression of periodontitis? Is the risk factor consistently associated with chronic periodontitis severity or progression?

A risk factor is often defined from an epidemiological perspective as an exposure that is associated with a particular clinical outcome,[42] whether or not the relationship is causal. As periodontitis initiation or progression must be observed over many years, clinical validity is often based on multiple confirming association studies. Randomized controlled intervention studies directed at modifying a specific risk factor provide the most convincing evidence of a risk factor's causality, but such studies are difficult to perform in periodontal disease, and few exist. Fortunately, there are well-described criteria for assessing the likelihood of causality of a disease-associated risk factor.[43] The criteria for clinical validity of risk factors in periodontal disease must start with consistent association of the factor with well-defined periodontal outcomes in appropriate populations. For some clinical uses we may be happy to have a marker that helps predict a maintenance patient's future likelihood of progression without concern of whether the marker is causal; for example, a certain level of bleeding on probing at multiple visits is a very good predictor of future progression, even though bleeding itself is not causing the progression.[44,45]

However, risk factors that are "causal" provide an opportunity to target the risk factor to prevent or treat disease. Given consistent associations of a risk factor with a periodontitis phenotype, one's confidence in the causality of the factor increases based on the following: (i) biological plausibility; (ii) biological gradient or dose-response relationship; (iii) temporal relationship (ie, does exposure to a putative causal factor precede disease phenotype?); and (iv) experimental evidence that tests a causal relationship

hypothesis.[43] A risk factor with a consistent association and evidence to support causality is more likely to influence a particular clinical outcome.

As most individuals exposed to bacterial accumulations on the proximal surfaces of their teeth for long periods of time will develop mild periodontitis with a few localized sites of moderate periodontitis, the primary importance of risk factors and individual risk for periodontitis relates to a more severe phenotype. Individual risk for periodontitis is important to help identify patients who are more likely to: (i) develop moderate-to-severe generalized periodontitis; (ii) exhibit clinical progression in the face of standard periodontal therapy; and (iii) have periodontitis that influences a development or treatment outcomes of systemic diseases.

2.3 | Step 3: clinical utility refers to the likelihood that information about a specific risk factor or set of risk factors will lead to actions that improve health outcomes

> Key point: *Risk factor clinical utility for a complex chronic disease such as periodontitis: Individualizing risk generally requires multiple risk factors and a way to integrate the influence of multiple risk factors in a single individual.*

Clinical utility requires the application of risk factors to classify individuals into discrete groups in order to guide disease prevention or intervention. Many factors with very strong association data may not make good classifiers.[46,47] Garcia et al[48,49] have provided excellent discussions of the limited predictive value for some powerful risk factors in multiple diseases, and they also illustrate the challenges of predicting risk for an individual patient, which of course is critical to clinical value. In addition, Garcia et al[48,49] note that many risk factors must be included to predict the majority of risk for death attributable to coronary artery disease. Although an individual risk factor may not be impressive in predicting the total population risk of a specific complex disease, some single risk factors (eg, blood cholesterol) have proven to be very valuable for guiding use of statins to achieve low levels of low density lipoprotein cholesterol, and thereby reducing cardiovascular disease events, including myocardial infarctions and deaths.

Although many patients are at risk for cardiovascular events as a result of other risk factors, an initial set of risk factors can be used to guide treatment for an important segment of the at-risk population. Such an approach also adds value by determining residual risk in some patients after treatment based on the strongest risk factors initially identified. For example, in a randomized controlled clinical trial of more than 15,000 overtly healthy adults with no prior history of cardiovascular disease and "normal" low density lipoprotein cholesterol levels (<130 mg/dL), the risk factor of elevated systemic inflammation (≥2 mg/L of C-reactive protein) was used to target individuals who might benefit from high dose statins that modestly reduce systemic inflammation. This was an effective strategy and

demonstrated that high dose statins lowered even "health-associated" levels of low density lipoprotein cholesterol and inflammation to prevent the first cardiovascular events, achieving a 54% reduction in risk of heart attack, based on actual reduction of clinical events compared with placebo.[50] In that intervention study based on successfully reducing the 2 strongest risk factors for cardiovascular events, a third-level risk factor, lipoprotein(a), was identified as a residual risk factor that, in spite of lowering already low levels of low density lipoprotein-cholesterol and systemic inflammation, this patient group needed a different therapeutic approach now identified by a third risk factor. Multiple new drugs targeting this third risk factor, lipoprotein(a) are in late stage development.[51]

In periodontitis, there are few studies that have been explicitly designed to test the hypothesis that risk stratification with specific factors, such as smoking, type 2 diabetes, obesity, genetics, or others, influence periodontal outcomes of therapy or preventive care.[21,52-54] If biases are properly considered and adequate sample sizes are available, it is possible, in some situations, to use large retrospective databases to ask prospective questions relative to the influence of patient stratification on disease prevention or treatment outcomes. This "prospective-retrospective" study design is being used routinely in the effort to discover and validate biomarkers to guide the use of new drugs that are expensive and have the potential for serious adverse drug events.[55]

2.3.1 | Risk factors should be moved to the clinical utility stage as early as possible

With common, but complex, chronic diseases, our goal should be to improve clinical management of the disease. As the decision analysis gurus teach us, there are no facts about the future, only probabilities. Prospective pilot studies allow us to unravel the relative importance of multiple factors in critical disease endpoints, such as disease progression and response to specific interventions.

2.3.2 | What are the practical elements required to get to clinical value?

Clinical utility indicates that there is a difference in the disease that is sufficient to influence the disease progression/severity (and therefore tooth loss and replacement), response to treatment, and systemic implications. The key question to be studied for clinical utility therefore goes beyond a simple disease association. The clinical utility question often has 3 parts: (i) if a specific patient is in one specific risk classification and (ii) is treated with different well-defined approaches, (iii) what is the actual observed frequency of a specific outcome?

2.4 | Individualized periodontal medicine starts with stratifying patients into specific buckets

Although individualized periodontal medicine suggests that an individual patient may have a unique biological fingerprint and therefore receive a unique therapy, this is not the reality in most chronic diseases. Individualizing risk must begin with criteria that allow every patient to be stratified into discrete and nonoverlapping categories (Figure 3). Stratification is often a key part of the clinical utility phase because it must build on learnings during the discovery phase. Risk factors that are highly significant during the discovery phase may not be informative in stratifying individuals for clinical purposes.[46,47] Complex diseases do involve thousands of interacting factors that probably could define a unique phenotype for every individual. Biological pathways that influence a complex disease in a specific individual interact, but some nodes in a pathway are more important than others and have leverage to change the disease outcome.[30] As with most chronic diseases,[56] the evidence suggests that individuals with periodontitis follow a small number of clinical paths that describe progression and severity patterns in the population. Similarly for periodontitis patients treated using standard principles, 70%-80% of patients respond predictably and favorably[10,12] with the others either not complying with regular maintenance care or being enriched with a small number of risk factors.[13-18,23,24,57-59]

2.5 | Stratification may be simple or complex

Current regeneration technology offers impressive opportunities to enhance supporting periodontal tissues and prolong retention of teeth. Predictable and useful periodontal tissue regeneration requires stratification of patients and sites to provide the most effective long-term outcomes.[60] Such stratification may use simple or complex patterns. Many parameters that are highly significant predictors of outcomes in large case-control studies may not be good "classifiers".[46,47] The important aspect of good classifiers for practical clinical use is that specific parameters can be used separately or combined into a well-defined pattern that classifies individual patients into distinct categories that are of clinical value.

2.5.1 | Simple stratification

Recombinant human platelet-derived growth factor BB homodimer may provide very good long-term regenerative success in certain sites and for certain patients. A group of clinical investigators reported good long-term advantages over the scaffold alone, but only for smokers[61] (Figure 4).

Although single risk factors are unlikely to be highly informative in observational studies of complex diseases, it is not uncommon to see single risk factors stratify responses to therapy or influence progression of complex diseases. For example, in a clinical trial of 7,018 high-risk cardiovascular disease patients randomized to the American Heart Association low-fat diet or the Mediterranean diet and followed for more than 4 years, a single genetic factor (TCF7L2) explained a 3-fold increase in stroke for individuals on the low-fat diet.[62] In addition, the Mediterranean diet essentially eliminated all added risk for strokes attributable to the TCF7L2 genetic effect. Other studies have reported that single genes, unrelated to drug metabolism, can have a major effect on clinical outcomes of drug therapy for chronic diseases.[63,64] To demonstrate clinical value in

FIGURE 3 The first and essential step in individualizing risk for periodontitis, and ultimately individualizing prevention and treatment, is having predefined criteria that stratify every patient into well-defined categories that are mutually exclusive


FIGURE 4 Bone regeneration in certain types of periodontal defects was enhanced by the use of recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB), but the substantial long-term regenerative potential was observed primarily in smokers, as noted by the amount of bone gain in the smokers treated with platelet-derived growth factor (blue solid line) compared with the smokers who received the scaffold alone (green solid line). The linear bone gain figure is reproduced with permission from Nevins et al.[61] The clinical and radiographic images are courtesy of Professor William Giannobile, University of Michigan

patient stratification, we should try as much as possible to ask a question about disease progression over time or response to treatment over time in prospective studies.

Not only do questions of disease progression and response to treatment allow us to get close to clinical utility, we also avoid multiple challenges inherent to case-control studies of periodontal disease. Two of the major challenges of periodontitis in observational studies are: (i) extraction of 6-8 teeth can convert a case of moderate-to-severe generalized periodontitis into a case of mild disease with 20 remaining teeth; and (ii) multiple factors, such as smoking, appear to influence the initiation and progression of periodontitis.[65-67] The first challenge produces an incorrect classification of the patient. If one is studying genetic factors in severe periodontitis, false positives may be present when a specific genetic factor is present but extractions have produced a patient classified as having mild periodontitis. The second challenge produces a dilution of the effect size of any single factor (ie, "many roads lead to Rome") and the statistical management of multiple

risk factors may mask their individual differences in terms of disease phenotype and biology.[37]

> Key point: *How can one possibly combine multiple risk factors to establish the net risk for a single individual?*

In periodontal disease, one of the biggest challenges is how to account for missing teeth in cross-sectional or case-control studies. Prior history of periodontitis is strongly associated with future risk. When there are multiple putative risk factors, one should start with a few classic risk factors, such as smoking and type 2 diabetes. Initial studies should demonstrate significant association between the core set of risk factors and sequentially add exploratory or novel risk factors to assess whether, for a specific phenotype, the exploratory risk factor adds value to classic risk factors in this disease. Perhaps most importantly some risk factors modify the effect of classic risk factors on the disease outcome.[24,59,68,69]

2.5.2 | Complex stratification

Practical application of a risk factor model that includes multiple risk factors is challenging, but essential for clinical utility for 2 primary reasons:

- It recognizes that for complex diseases there are multiple physiological pathways that can lead to disease. To focus on only one of those pathways may result in many false negatives, as other factors may lead to the same phenotype.
- Multiple risk factors may be additive, and in some cases conditional. For example, the Framingham Risk Score estimates an individual's 10-year risk for developing diagnosable coronary artery disease. Translation of the score into risk depends on an age- and gender-based algorithm that combines multiple factors, such as total cholesterol, blood pressure, and smoking. One can input a range of values for the risk factors and quickly see that using a single factor accounts for a limited part of the total risk for someone of a specific age and gender.[70] In addition, some risk factors, such as lipoprotein(a), that have been determined to be causal for coronary artery disease,[71] do not appear to result in major cardiovascular disease events unless there is a second factor present that amplifies the inflammation.[69]

The Periodontal Risk Assessment system, as developed and described by Lang & Tonetti [14,17,72] and shown in Figure 5, is one example of tools that integrate multiple risk factors in assessment of periodontitis. The Periodontal Risk Assessment system allows the identification of individuals who may be at risk for disease progression as a result of multiple known and unknown factors. The risk may or may not involve an interaction between risk factors, but one of the strengths of the system is that it acknowledges a broad range of risk factors without forcing the system to include all factors.

More complex interpretations of multiple risk factors in a prediction model, of course, depend on having a broad range of data that allow validation of the value of the tool for different patients in different scenarios.

It is reasonable to use selected risk factors together in a simple additive model (ie, a patient with any 2 risk factors is assumed to be at greater risk than a patient with no or only or 1 risk factor). Such models may use regression data to assign a quantitative magnitude of effect to each risk factor, or risk factors can be assumed to be of equal effect. In simple multifactorial risk models, it is important to predefine the risk interpretation of different possible combinations.[21] If adequate databases are available with well-defined progression data or clinical event data, one may evaluate the impact of adding new risk factors to a standard risk model by means of calculating a "net reclassification index"[73-75] which determines whether the new risk factor changes the risk classification of specific individuals to a clinically meaningful extent.

For many years some investigators have studied multiple aspects of chronic periodontitis with increasing attention to biomarker clusters that stratify subsets of chronic periodontitis.[76-79] Because complex chronic diseases, by definition, involve multiple genes and multiple environmental factors that interact with many permutations, theoretically we may all be uniquely different at the molecular level. The challenge becomes how to set the granularity to a level that is


FIGURE 5 Periodontal risk assessment system, as defined by Lang and Tonetti[14] in 2003. The graphical representation of risk uses a spider web image in which each axis of the web is a risk factor and each increment from the center of the web outward allows the clinician to indicate the patient's level of risk for each specific risk factor. The visual image provides a clear impression of a patient's composite risk. The figure is reprinted with permission from Oral Health & Preventive Dentistry.[14] BL, bone loss; BOP, bleeding on probing; Envir., Environmental factors; Gen., genetics; PD, probing depth; Syst., systemic disease

clinically meaningful. The challenge of translating the biological complexity into actionable targets has been addressed recently, relative to cardiovascular disease, where the use of loss- or gain-of-function mouse models has implicated dozens of molecular targets as major drivers of atherosclerotic cardiovascular disease, yet few of these targets have been shown to be causal and to have value in preventing or treating clinical disease.[30]

The challenges are how to move from single parameter discovery to the integration of multiple parameters and then to actual classification of individual humans. That is ultimately what we are asked to do when one changes the question from, "What are the major risk factors for periodontitis?" to "How can we identify an individual's risk for progression or severity of chronic periodontitis?"

In recent years, some groups[21,79] have explored various approaches to stratifying individuals relative to chronic periodontal disease. As they and others experienced, biological explorations of chronic periodontitis using -omics approaches have not been greatly rewarding, perhaps in large part because of inherent weaknesses of periodontal observational databases for which a single phenotype is assumed.

Dr. Offenbacher and his colleagues used a large cross-sectional database with periodontal data to identify a set of complex traits based on prespecified parameters, such as microbial patterns defined by 8 periodontal bacterial pathogens and the status of periodontal inflammatory response as measured by interleukin-1beta levels in gingival crevicular fluid.[80] Six patterns were identified based on 2 biological characteristics, markers of specific microbial ecologies, and periodontal levels of inflammation. These 6 biologically defined patterns allowed each patient in the database to be matched to 1 of the specific patterns. The team could then explore genetic differences among the 6 biologically defined complex traits. This approach has multiple important advantages, for example: the biology defined by a pattern has a narrowed search space relative to genetic influences, not unlike focusing on disease progression or response to treatment; and every patient can be classified. Both of these study characteristics are important to advance toward clinical utility because the starting point for studying the potential value of individualized risk for periodontitis is being able to classify every patient into a predefined category.

Offenbacher et al[77] have recently advanced the stratification to attempt to define clinical substructure in the disease to untangle chronic periodontitis into multiple well-defined clinical classifications. This again represents an important starting point to use the newly validated classifications to explore specific hypotheses about disease progression or different responses to periodontal therapy.

3 | USING CURRENT EVIDENCE TO INDIVIDUALIZE RISK FOR PERIODONTITIS

The vast majority of individuals will develop periodontitis when exposed to an undisturbed subgingival bacterial mass over time. Observational studies indicate that most periodontitis will result in mild disease with a few local sites with moderate disease, regardless

of the bacterial challenge.[8,9] Evidence from interventional studies supports a predictable periodontitis response to bacterial control in a majority of patients.[10,11,81-87] The challenge, as specialists, is to identify subsets of patients who respond differently to bacterial challenge and either express more severe periodontitis or do not respond predictably to standard clinical approaches to periodontitis prevention and treatment. Thus, periodontists need to conduct research to define how to stratify patients, in order to identify those who require a different approach to clinical management and to develop clinical protocols for efficient prevention and treatment of more complex cases.

3.1 | Clinical Scenario 1: primary prevention of periodontitis at the population health level

If our goal is to reduce the prevalence of periodontitis among adults in a specific population, this is a population health initiative that is in part an access-to-care issue and an education issue. For example, in the USA, epidemiological data indicate that periodontitis, and especially severe disease, is enriched in segments of the population below twice the federal poverty line.[20,88] The same enrichment for severe periodontitis is seen in very targeted geographic locations in the USA that are dominated by lower socio-economic and education attainment.[89] A second population that is enriched for severe periodontitis, at least as represented by tooth loss, comprises individuals who have good access to dental care through employee-based dental insurance but do not see a dentist regularly for preventive care.[21]

3.1.1 | Using individual risk factor information to focus periodontitis prevention messages

Beyond educating mothers, children and young adults about the importance of oral hygiene and oral hygiene methods, we can start to focus the messages on individual risks for periodontitis. Some of the emphasis should be on the value of preventing periodontitis with the individual risk role that smoking and uncontrolled type 2 diabetes plays in periodontitis severity and complications of tooth loss. Although we are discussing a population health message, the approach can include self-awareness messages of individual risk, and the action message should encourage regular professional periodontal assessments to identify and address periodontitis early and to educate about personal care. The individual risk message helps to personalize the risk and potential solutions for a patient's individual needs.

3.2 | Clinical Scenario 2: use of individual risk for periodontitis to prevent moderate-to-severe periodontitis in individuals with access to dental care

Routine primary preventive care to reduce the likelihood of periodontitis, as has been taught to dentists, hygienists, and patients for many years, is anchored by assumptions and expectations that are correct for the majority of our patients but fail to manage those

who are at greatest risk. This has been shown to be true even for adult patients who have been managed according to the well-proven "needs-related" approach to preventive dental care, as defined by Axelsson et al.[90,91]

The current approach to primary preventive periodontal care in general dentistry includes 2 faulty assumptions and one incorrect expectation.

- The first faulty assumption is that all patients are equally susceptible to periodontitis, and the clinical expression of periodontitis results entirely from exposure to bacterial plaque over time.
- The second faulty assumption is that periodontitis progresses slowly, so once a patient is identified with mild periodontitis, standard protocols will predictably manage the disease. The treatment approach generally used in such situations involves repeated prophylaxis with scaling and root planing as indicated in the isolated sites that show early periodontitis. Such approaches may be augmented with targeted interproximal oral hygiene instructions and local delivery of antimicrobials.
- The incorrect expectation of the primary prevention outcomes is described above, and this is that a patient with early mild periodontitis will respond predictably to the scaling and root planing of the sites with localized mild disease. The current standard in most dental offices throughout the world is that scaling and root planing management of mild periodontitis rarely has a follow-up visit to assess response of the patient. This, of course, is based on the reality that most patients will in fact respond very predictably to such a therapeutic intervention.

4 | OPPORTUNITIES TO ADD CLINICAL VALUE BY INDIVIDUALIZING RISK FOR PERIODONTITIS

The curves shown in Figure 6 postulate what to expect in individuals who see a dentist regularly for routine preventive care. The question is, "What can we expect to see in terms of periodontitis progression to moderate-to-severe generalized periodontitis in patients who are part of the regular dental care system?" There are large dental insurance databases, managed dental care databases, and nationwide epidemiology findings that can provide some insights to answer this question, but we must acknowledge the limitations. To some extent, the boundaries of periodontitis expression may be seen in the studies of populations in Sri Lanka and Tanzania with minimal to no personal oral cleaning and no professional cleaning.[8,9] Although not analogous to patients in routine dental care in the USA, Europe, and Asia, the maximum disease boundary may be a good disease stratification perspective as one envisions applying such boundaries to individuals with access to routine dental care.

Most patients (as shown by the blue line in Figure 6) will have mild disease detected at some point and with appropriate preventive care will develop predominantly mild periodontitis with a few

localized sites with moderate disease. The gray line is intended to represent the 8%-10% of individuals who are on a different path. The X and Y points on Figure 6 are on 2 different theoretical periodontitis progression curves; yet, to the clinician, the periodontal assessment is likely to appear the same. Based on current knowledge of periodontitis, the age differences at the time of the first clinical diagnosis of mild periodontitis are unlikely to be remarkable. Although current evidence suggests that patients on the gray line are enriched with a small set of clinically important risk factors, and they may be noted by the clinician, there has not been sufficient evidence to manage the cases differently, given the clinical findings of mild periodontitis in both patients at their initial examination.

5 | PRIMARY PREVENTION AND TREATMENT OF MILD PERIODONTITIS

> Key point: *Do we have evidence that for patients under the routine care of dentists, individual risk assessment adds value to guide primary periodontitis prevention or treatment of mild periodontitis?*

In many ways, this question is really asking the P4 medicine question of whether we can predict which periodontally healthy patients are more likely to be on the gray line than the blue line (Figure 6) because the individual on the gray line is projected to have clinically important progression of periodontitis, leading to complications such as tooth loss. We already know that most patients, even with only moderate oral hygiene, are likely to develop only mild periodontitis with—at most—a few localized sites of moderate disease. So, the problem in clinical practice is that a clinician is well justified to approach primary prevention of periodontitis or treatment of mild periodontitis with localized moderate disease with the incorrect assumptions and expectations noted above because our evidence indicates that most of the patients who dentists see are unlikely to progress to more severe periodontitis and complications, regardless of whether or not they are treated more intensively. It makes sense for us to alter our current approach to primary periodontitis prevention and treatment of mild disease only if we can do 2 things: (i) use tools which reliably increase the probability that we can identify an individual patient who is more likely to be on the gray path than the blue path; and (ii) obtain evidence that a different approach to prevention or early treatment would make a difference to the individuals on the gray path in terms of reducing the severity and complications of periodontitis.

Axelsson et al[90,91] randomly identified 50-year-old subjects in the Swedish county of Varmland and performed comprehensive oral examinations at baseline and 10 years later. By report, Axelsson noted that more than 95% of the subjects had regular preventive dental care at needs-related intervals. As a result of relatively good preventive care during the 10-year period, the mean tooth loss per subject per 10 years was <0.4 teeth, and those patients who lost 2

FIGURE 6 Given current knowledge of the epidemiology of periodontitis severity and extent in the USA, we can postulate 3 curves of periodontitis severity according to age of subject. One of those curves (green) represents individuals with minimal to no periodontitis through middle age[9] but who will probably develop mild to localized moderate periodontitis in later years.[121] The blue line represents individuals who will have mild disease and, with appropriate preventive care, will develop predominantly mild periodontitis with a few localized sites with moderate disease. The gray line is intended to represent the 8%-10% of individuals who are on a different path. Time point X and Y identifying two patients with the same periodontitis severity, but X identifies a patient who should be monitored more closely than Y patient because patient X developed clinical disease at an earlier age

or more teeth from clinically confirmed periodontitis were identified. At the 10-year examination, buccal swab samples were collected for interleukin-1 genetic analysis. Using 2 risk factors—smoking and interleukin-1 genotype positivity[92]—individual patients were stratified by 0, 1, or 2 risk factors, as shown in Figure 7, and analyzed for frequency of patients losing 2 or more teeth from periodontitis.

Guided by Axelsson's findings, a periodontitis prevention study was designed, asking the following questions: "In dental patients with no prior diagnosis of periodontitis and none of 3 previously validated risk factors, do 2 professional cleanings each year lead to less tooth loss compared with 1 cleaning annually?"[21]; and "In patients with predefined risk factors do those with 2 cleanings annually have a lower frequency of tooth loss than those with 1 cleaning annually?"

The clinical validity relative to assignment of individual risk for periodontitis may be assessed by demonstrating that risk stratification of individual patients leads to different outcomes. Important outcomes relative to chronic periodontitis include disease progression, development of complications such as tooth loss, progression following treatment, and impact on selected systemic diseases. As discussed above, risk stratification clinical utility indicates that the risk information can guide specific clinical prevention plans that are more likely to lead to a difference in disease outcomes than managing all patients as if they have the same susceptibility to disease progression. In this study, the predefined specific interventions were 1 or 2 clinical examinations and prophylaxes annually in dental patients with no history of periodontitis (Figure 8).

As it is not practical to ask the above questions in a randomized controlled clinical trial for more than 10 years in patients undergoing

different frequencies of preventive dental care, the investigators adopted the experimental principles recommended for the study and regulatory submission of biomarker performance evidence in previously collected large databases.[55] Study inclusion criteria, end points, and risk stratification criteria were predefined (Table 1). This was a clinical utility study of a predefined risk assessment tool (ie, presence of any of 3 risk factors constituted increased risk for tooth loss, and such patients were designated "high risk." The study was designed and powered based on the primary clinical utility question. The study was not intended or powered to assess end-point associations with any single risk factor. The primary clinical utility question was approached as one would for any new technology of potential clinical value. The primary question therefore involves a simple calculation of frequency of low-risk patients with tooth loss during the monitoring period of 16 years, depending on whether their preventive regime consisted of 1 cleaning per year or 2 cleanings per year (Table 2).

In this population of adults there appears to be a background level of tooth loss of 14%-15% that is not reduced by regular and consistent prophylaxes twice yearly for 16 years, even in patients with none of the 3 risk factors. Some of the tooth loss that does not appear to be reduced by regular preventive care may be attributable to conditions such as root or crown fractures that do not benefit directly from dental prophylaxes. In addition, in patients with any 1 of the 3 prespecified risk factors, 2 cleanings annually reduced tooth loss comparable with the patients who had none of the risk factors. In patients with 2 or 3 of the risk factors, 2 cleanings annually do not appear to be sufficient to reduce tooth loss to the level seen in patients with none or 1 risk factor.

FIGURE 7 Ten-year follow-up in randomly selected 50-year-old individuals from one county in Sweden. Most individuals had regular preventive care with their dentist during the 10 years after the initial clinical assessment. The follow-up clinical examinations were used to identify periodontal changes in a well-maintained adult population. In addition, the frequency of patients who lost 2 or more teeth from clinically confirmed periodontitis were calculated based on 2 predefined risk factors: smoking and interleukin-1 (IL-1) genotype. [1]Percentage this risk group represented in the total sample (n = 276). [2]P = .0016, Fisher's exact test.[90,91] Smokers were current smokers at baseline. Positive (POS) or negative (NEG) status for IL-1 genotype was predefined as described previously[21]


FIGURE 8 Patient stratifications in the Michigan Personalized Prevention Study.[21] The study outcomes were frequency of patients in each group who lost teeth during the 16 years of claims history. IL-1, interleukin-1

Can we today identify individual risk for periodontitis? Evidence supports that for adults without a clinical diagnosis of periodontitis, patients can be objectively stratified into 2 or 3 risk categories that differentiate clinical responses to different frequencies of preventive care administered in clinical practice by general dentists and hygienists. In this context, a risk profile defined by 3 risk factors appeared to add value to clinical assessments by the patients' own dentists.

5.1 | Clinical Scenario 3: guide treatment and monitoring of periodontitis and secondary prevention

One of the objectives of applying precision medicine to periodontitis is to be able to identify patients with periodontitis who may benefit from more intensive therapy during the primary treatment of their periodontitis or during their maintenance care. More intensive therapy may include more intensive bacterial control using systemic or local antimicrobials and/or more frequent maintenance care. Furthermore, more intensive therapy may also include enhanced efforts to control risk factors more effectively, such as control of type 2 diabetes and more direct control of inflammation through prescription of drugs[93,94] or by nutritional approaches.[95]

Do we have evidence that individual risk assessment adds value to guide treatment and secondary prevention for patients with periodontitis who are under the routine care of dentists or periodontists?

There are multiple retrospective studies of various risk factors relative to outcomes of periodontal active treatment and maintenance care.[13-16,18,96] These studies were small in size and did not assign a composite risk to each individual patient and then quantify

TABLE 1 Description of the Michigan Personalized Prevention Study[21]

1. Potential subjects were selected from a large anonymized dental insurance claims database (Delta Dental of Michigan) guided by predefined criteria. Entrance criteria were previously reported,[21] with some of the key criteria for participation as follows:
   a. Age 35-57 years at first dental insurance claim
   b. No history of periodontitis, based on dental claims data
   c. Have employer-based dental insurance through same employer and payor for more than 15 years
   d. Dental insurance for individuals without periodontitis covered the cost of 2 examinations and dental prophylaxes annually
   e. Patients attended their dentist of choice consistently for either 1 or 2 dental prophylaxes every year for more than 15 years. Criteria for patients with consistent attendance for 1 prophylaxis annually for 16 consecutive years, or consistent attendance for 2 annually, are described in the manuscript [21]
2. 25,452 patients met all criteria for inclusion and were invited to participate, which included consent to access dental insurance claims, consent for specified genetic analysis and submission of a DNA sample, and a medical history. 5117 patients agreed to participate and all data were complete
3. All entered patients were classified as either "low risk" or "high risk," based only on predefined criteria
   a. Low risk: none of 3 predefined risk factors: smoking, type 2 diabetes, positive for interleukin-1 genetic variations previously shown to be proinflammatory and associated with severe or progressive periodontitis
   b. High risk: positive for any 1 of the 3 predefined risk factors: smoking, type 2 diabetes, interleukin-1 genetic variations
4. Smoking history and diabetes history were collected by patient responses to questionnaires
5. No effort was made to assess the quality of professional cleanings because the study involved several-hundred general dentist offices
6. Primary endpoint for analysis was frequency of patients in each risk group with tooth loss during the 16-year monitoring period
7. Primary question: In patients classified as low risk based on having none of the specified 3 risk factors, did 2 cleanings annually reduce tooth loss compared with 1 cleaning annually?

outcomes of treatment based on the individual risk calculated. There was no clear approach to reduce bias. For example, patients with infrequent compliance with maintenance care may have poorer health habits overall compared with those who attend maintenance visits on a regular frequency. These studies provide good preliminary evidence to guide design of a definitive study of individualized risk for periodontitis and outcomes of treatment. No previous studies have looked at periodontitis treatment outcomes, specifically to compare individualized risk with outcomes of different therapies.

5.2 | Clinical Scenario 4: guide periodontal treatment to assist prevention and management of certain systemic diseases

Substantial evidence supports an independent influence of periodontitis on certain systemic diseases, including type 2 diabetes, stroke, and coronary artery disease.[97-101] The associations between periodontitis and adverse pregnancy outcomes and

development/progression of rheumatoid arthritis appear to relate directly to the effects of specific oral bacteria, which may be challenging to study relative to the effect of preventing or treating periodontitis .[102-105]

A very different goal for identifying an individual's risk for periodontitis may be to reduce the likelihood that their periodontitis influences that patient's systemic health. This statement assumes that the systemic influence of periodontitis is not a simple function of the clinical severity of an individual's periodontitis; however, the evidence for that conclusion is very limited.

Is there evidence that individual risk assessments add value to guide periodontitis treatment to prevent systemic implications of the periodontitis or improve systemic disease?

The practical question is if, for patients with moderate-to-severe generalized periodontitis, there is a way to risk-stratify the patients to identify those who would be likely to benefit from more intensive treatment and monitoring to reduce risk for certain systemic diseases and their complications. And is there any evidence that some patients with mild-to-localized moderate periodontitis can be risk stratified to guide more intensive treatment and monitoring to reduce the risk for certain systemic diseases?

6 | WHAT POTENTIAL MECHANISMS MOST PLAUSIBLY EXPLAIN THE ASSOCIATION OF PERIODONTITIS WITH OTHER SYSTEMIC DISEASES?

When periodontitis is present, 2 intertwined general mechanisms—inflammation and direct bacterial action—can theoretically activate disease-implicated pathways in various tissues that are distant to the periodontium. One mechanism involves activation of acute phase proteins in the liver which initially help to amplify systemic inflammatory components that broaden protection against the bacterial challenge. The acute phase proteins, such as C-reactive protein, can be activated by components from bacteria in the periodontal pocket gaining access to the bloodstream through the pocket epithelium and reaching and activating hepatocytes. In addition, inflammatory mediators in gingival tissue may enter the circulation and activate the acute phase response. The inflammatory mediators activated in the liver may lead to tissue damage if not switched to a repair mode. Separately, with untreated moderate-to-severe periodontitis, periodontal bacteria may enter the bloodstream through the pocket wall and potentially localize to damaged tissues, such as denuded vascular endothelium. One could speculate that moderate-to-severe periodontitis is likely to activate both systemic inflammation directly and also seed periodontal bacteria into the circulation.

Inflammation in an individual's finger, whether activated by a bacterial infection or trauma, can activate the acute phase response in the liver by means of circulating cytokines produced at the initial site of inflammation. Periodontitis activates production and release of acute phase proteins from the liver, with C-reactive protein being the most

TABLE 2 Role of individualized patient risk and frequency of cleanings relative to observed frequency of long-term tooth loss in patients without a history of periodontitis, as reported in the Michigan Personalized Prevention Study[21]

|	Low risk n = 2418	High risk n = 2699	High risk n = 2699	
			Any 1 risk factor n = 2165	2 or 3 risk factors n = 534
Number of annual prophylaxes				
1	0.16	0.22	0.20	30
2	0.14	0.17	0.15	23

Frequency of patients in the designated risk group who lost 1 or more teeth during the 16 years of dental claims history.

[a]In low risk individuals (none of 3 risk factors), 2 prophylaxes per year was not superior to 1 prophylaxis per year (P = .092).

[b]In high risk individuals (1 or more of 3 risk factors), 2 prophylaxes per year was superior to 1 prophylaxis per year (P = .002).

[c]In high risk individuals with any 1 of 3 risk factors, 2 prophylaxes per year was superior to 1 prophylaxis per year (P = .007).

[d]In high risk individuals with any 2 risk factors or all 3 risk factors, 2 prophylaxes per year was not superior to 1 prophylaxis per year (P = .108).

Experimental groups: matched cohort study- UK clinical practice research datalink

- Psoriasis:
  - Severe   n = 5648
  - Mild   n = 85 232
- Bullous skin diseases   n = 4284
- Ulcerative colitis   n = 12 203
- Crohn's disease   n = 7628
- Systemic vasculitis   n = 6283

- Inflammatory arthritis   n = 27 358
  - Rheumatoid arthritis
  - Psoriatic arthritis
  - Ankylosing spondylitis
  - NOT osteoarthritis
- Systemic autoimmune disorders n = 7472
- **Matched controls**   n = 373 851

Increased frequency of T2D, stroke, CAD

Inflammatory disease	Type 2 diabetes (%)	Stroke (%)	Coronary artery disease (%)	2 or more outcomes (%)
Mild psoriasis	17***	8	3	15**
Severe psoriasis	30**	0	29**	48*
Crohn's disease	0	0	10	16
Systemic vasculitis	33***	31*	23*	51***
Bullous skin disease	20	35*	12	57***

FIGURE 9 Individuals with a prior diagnosis of specific chronic inflammatory diseases were identified in the UK Clinical Practice Research Datalink and were compared by means of a matched cohort study with individuals with no prior diagnosis of any of the listed chronic inflammatory diseases. The study endpoints were frequency of type 2 diabetes, stroke, or coronary artery disease, in a specific chronic inflammatory disease, such as bullous skin disease, compared with the frequencies in the matched control group of none of the chronic inflammatory diseases.[112] ***P = .001; **P < .01; *P < .05

well documented acute phase protein. The level of C-reactive protein is higher in blood in individuals with periodontitis (P = .001) and the C-reactive protein level is associated with the number of periodontally active sites.[106] The more severe and more generalized the periodontitis case, the greater the association with increased C-reactive protein.[107,108] Patients with severe periodontitis are more likely to have C-reactive protein levels of ≥3 mg/L, which is associated with substantial increased risk of cardiovascular diseases.[109] Depending on the severity of the periodontitis and bleeding on probing, sites with more disease have higher periodontal inflamed surface area scores.[110] Based on available evidence, it is reasonable to expect that patients with untreated or inadequately treated moderate-to-severe periodontitis will be more likely to have elevated C-reactive protein levels and more bacteremias involving periodontal bacteria. In addition, recent evidence indicates that higher periodontal inflamed surface area scores are associated with higher medical costs.[111]

Periodontitis is certainly not the only chronic inflammatory disease associated with increased frequency and severity of other systemic diseases. Several chronic inflammatory diseases that have no direct bacterial component increase blood levels of C-reactive protein and are associated with increased prevalence of certain systemic diseases. Investigators recently used the large UK Clinical Practice Research Datalink to test the role that "systemic inflammatory burden" may play in the initiation of coronary artery disease, stroke, and type 2 diabetes[112] (Figure 9).

Several important conclusions can be drawn from the results of this study of chronic inflammation and systemic inflammatory burden. It is clear that certain chronic inflammatory diseases, but not all, increase the risk for type 2 diabetes, coronary artery disease, or strokes. Severity of chronic inflammatory disease appears to be important relative to risk for other diseases, and increased risk for

FIGURE 10 Increased severity of periodontitis as represented by quartile of probing depth was associated with increased risk of type 2 diabetes mellitus (T2DM) as assessed by fasting plasma glucose levels $\geq$126 mg/dL or a prior diagnosis of diabetes. The association was only present in individuals who also had elevated C-reactive protein (CRP) levels of > 3 mg/L.[113] Data were drawn from NHANES III (n = 5731; age > 20 years). Figure reproduced with permission from the *Journal of Periodontology*.[113] PD, probing depth

Risk for Type 2 diabetes mellitus

- 5297 periodontitis patients treated in periodontal clinic
- Treatment:
  - Oral hygiene instruction
  - Nonsurgical treatment phase
  - Re-evaluation
  - Residual pockets rescaled or surgically treated
  - Maintenance program
- 1 yr evaluation after active treatment: "Poor responder" if
  - >10% residual pockets > 4mm, AND
  - $\geq$20% sites with bleeding on probing

Treatment responder frequency and incidence of cardiovascular disease events in each responder group


FIGURE 11 Periodontitis patients who were treated in a specialist clinic but did not respond predictably to standard periodontal therapy and maintenance care had a higher incidence of cardiovascular disease (CVD) events in long-term follow-up (median, 16.8 years). Events included myocardial infarction, stroke, and heart failure [114]

one of the target diseases did not necessarily translate into risk for other target diseases.

Although the evidence is strong for an independent influence of periodontitis on certain systemic diseases, we should not assume that we have sufficient understanding of the biologic roles that periodontitis may play to design a successful intervention study.

It may be that periodontitis of a certain clinical severity has such a strong impact on a systemic disease, like type 2 diabetes, that intensive treatment of periodontitis will have a predictable effect on type 2 diabetes outcomes. It is also possible that intervention in one complex disease, such as periodontitis, may have a range of variations in the target complex disease, such as type 2 diabetes, and give variable outcomes.

Fortunately, studies are in progress by multiple groups to explore the complexity of periodontitis at the level of stratifying individual patients by risk for influencing other systemic diseases. For example, severe periodontitis, as defined by clinical measurements, was associated with fasting plasma glucose level as an indication of risk for diabetes. The investigators reported, as shown in Figure 10, that the

significant relationship between severe periodontitis and fasting plasma glucose levels was conditional on the patient also having blood C-reactive protein levels of greater than 3 mg/L.[113]

Exploration of the potential health benefits of controlling periodontitis requires studies that stratify patients by multiple risk factors to guide intervention and assess outcomes of targeted systemic diseases. Such work is in progress, as has been reported recently and is summarized in Figure 11.[114]

7 | HOW CAN WE START TO UNRAVEL RISK PROFILES THAT AUGMENT THE INFLUENCE OF PERIODONTITIS ON SYSTEMIC DISEASES?

One of our primary goals in exploring risk profiles is to help guide the use of periodontitis prevention and treatment to enhance management of certain systemic diseases. Evidence appears to support a role for periodontal bacteria in adverse pregnancy outcomes.[105,115-119]

For practical reasons, this discussion therefore will focus on the potential role of risk factors that influence systemic inflammation as a potential component of the periodontitis influence on certain systemic diseases. The emphasis on systemic inflammation is not to minimize the role of the microbiome in the potential periodontal risk for systemic diseases but merely to allow some focus to the discussion. Others can make a very coherent argument for taking a different approach, and this is likely to be well justified given our early stage of development.

The goal is to target, more precisely, the periodontal patients who are more likely to benefit from more intensive periodontal disease prevention and management.

There appear to be some dominant concepts as to how risk stratification may be important in assessing an individual periodontal patient's influence on specific systemic diseases.

- Concept 1: Periodontitis severity and extent of disease tells the entire story. Other factors may be involved but do not add value beyond periodontitis severity in planning to enhance management of, for example, type 2 diabetes, through more intensive treatment of periodontitis.
- Concept 2: Common risk factors, such as smoking, that are known to influence both periodontitis and coronary artery disease, independently add to or amplify the risk for systemic disease that is attributable to periodontitis alone. This does not discount the importance of periodontitis in the systemic risk but suggests that incorporating the smoking status in a risk profile adds value in planning the treatment of periodontitis for the purpose of helping to control risk for atherosclerotic cardiovascular disease events.
- Concept 3: It is a simple systemic inflammatory burden story. Periodontitis is probably an important component of the chronic systemic inflammatory burden that has been implicated in terms of risk for chronic diseases and their complications. The risk profile relative to guiding better management of chronic systemic disease may depend on integrating multiple factors that alter the inflammatory burden and may require control of multiple components in order to influence the systemic disease in question.

Concept 2 and Concept 3 above have some overlap but lead to different approaches to clinical action. Concept 1, if supported by strong evidence, may allow the periodontist to play an important role in control of chronic diseases; however, if Concept 3 is correct the periodontist is likely to become more integrated in health care.

Although periodontitis has a strong independent association with selected systemic diseases, most clearly uncontrolled type 2 diabetes, coronary artery disease, strokes, rheumatoid arthritis, and adverse pregnancy outcomes, the controlled intervention studies that have been undertaken have been generally promising in type 2 diabetes, with some inconsistency that suggests a lack of clear protocol or limited knowledge of relevant disease factors. The intervention studies in adverse pregnancy outcomes have not been rewarding.

8 | CONCLUSIONS

Individualizing risk of periodontitis is not, in my opinion, simply an interesting academic exercise, but perhaps an essential requirement to move the field of periodontitis forward.[120] As a result of great innovations and efforts by investigators and clinicians throughout the world, we have made enormous advances in our knowledge but now must move beyond retrospective observations and associations. Stratification of patients in short-term challenge models and in long-term intervention trials are perhaps the only ways to move forward in a process that may differentiate the value of periodontal specialist care. We must identify the complex cases that require different preventive and treatment protocols to demonstrate value in controlling local oral complications of periodontitis and value in assisting the management of chronic systemic diseases.

REFERENCES

1. Lang NP, Cumming BR, Loe H. Toothbrushing frequency as it relates to plaque development and gingival health. *J Periodontol.* 1973;44(7):396-405.
2. Loe H, Schiott CR. The effect of mouthrinses and topical application of chlorhexidine on the development of dental plaque and gingivitis in man. *J Periodontal Res.* 1970;5(2):79-83.
3. Loe H, Theilade E, Jensen SB. Experimental gingivitis in man. *J Periodontol.* 1965;36(3):177-187.
4. Page RC. The role of inflammatory mediators in the pathogenesis of periodontal disease. *J Periodontal Res.* 1991;26(3 Pt 2):230-242.
5. Lindhe J, Hamp S, Loe H. Experimental periodontitis in the beagle dog. *J Periodontal Res.* 1973;8(1):1-10.
6. Lindhe J, Hamp SE, Loe H. Plaque induced periodontal disease in beagle dogs. A 4-year clinical, roentgenographical and histometrical study. *J Periodontal Res.* 1975;10(5):243-255.
7. Loe H, Anerud A, Boysen H, Smith M. The natural history of periodontal disease in man. The rate of periodontal destruction before 40 years of age. *J Periodontol.* 1978;49(12):607-620.
8. Baelum V, Fejerskov O, Karring T. Oral hygiene, gingivitis and periodontal breakdown in adult Tanzanians. *J Periodontal Res.* 1986;21(3):221-232.
9. Loe H, Anerud A, Boysen H, Morrison E. Natural history of periodontal disease in man. Rapid, moderate and no loss of attachment in Sri Lankan laborers 14 to 46 years of age. *J Clin Periodontol.* 1986;13(5):431-445.

10. Hirschfeld L, Wasserman B. A long-term survey of tooth loss in 600 treated periodontal patients. *J Periodontol*. 1978;49(5):225-237.

11. Lindhe J, Nyman S. Long-term maintenance of patients treated for advanced periodontal disease. *J Clin Periodontol*. 1984;11(8):504-514.

12. McFall WT Jr. Tooth loss in 100 treated patients with periodontal disease. A long-term study. *J Periodontol*. 1982;53(9):539-549.

13. Eickholz P, Kaltschmitt J, Berbig J, Reitmeir P, Pretzl B. Tooth loss after active periodontal therapy. 1: patient-related factors for risk, prognosis, and quality of outcome. *J Clin Periodontol*. 2008;35(2):165-174.

14. Lang NP, Tonetti MS. Periodontal risk assessment (PRA) for patients in supportive periodontal therapy (SPT). *Oral Health Prev Dent*. 2003;1(1):7-16.

15. Lang NP, Tonetti MS, Suter J, Sorrell J, Duff GW, Kornman KS. Effect of interleukin-1 gene polymorphisms on gingival inflammation assessed by bleeding on probing in a periodontal maintenance population. *J Periodontal Res*. 2000;35(2):102-107.

16. McGuire MK, Nunn ME. Prognosis versus actual outcome. IV. The effectiveness of clinical parameters and IL-1 genotype in accurately predicting prognoses and tooth survival. *J Periodontol*. 1999;70(1):49-56.

17. Persson GR, Matuliene G, Ramseier CA, Persson RE, Tonetti MS, Lang NP. Influence of interleukin-1 gene polymorphism on the outcome of supportive periodontal therapy explored by a multi-factorial periodontal risk assessment model (PRA). *Oral Health Prev Dent*. 2003;1(1):17-27.

18. Pretzl B, Wiedemann D, Cosgarea R, et al. Effort and costs of tooth preservation in supportive periodontal treatment in a German population. *J Clin Periodontol*. 2009;36(8):669-676.

19. Paulander J, Axelsson P, Lindhe J, Wennstrom J. Intra-oral pattern of tooth and periodontal bone loss between the age of 50 and 60 years. A longitudinal prospective study. *Acta Odontol Scand*. 2004;62(4):214-222.

20. Eke PI, Wei L, Thornton-Evans GO, et al. Risk indicators for periodontitis in US adults: NHANES 2009 to 2012. *J Periodontol*. 2016;87(10):1174-1185.

21. Giannobile WV, Braun TM, Caplis AK, Doucette-Stamm L, Duff GW, Kornman KS. Patient stratification for preventive care in dentistry. *J Dent Res*. 2013;92(8):694-701.

22. Gorman A, Kaye EK, Nunn M, Garcia RI. Changes in body weight and adiposity predict periodontitis progression in men. *J Dent Res*. 2012;91(10):921-926.

23. Meisel P, Kohlmann T, Nauck M, Biffar R, Kocher T. Effect of body shape and inflammation on tooth loss in men and women. *Clin Oral Investig*. 2016;21(1):183-190.

24. Meisel P, Schwahn C, Gesch D, Bernhardt O, John U, Kocher T. Dose-effect relation of smoking and the interleukin-1 gene polymorphism in periodontal disease. *J Periodontol*. 2004;75(2):236-242.

25. Wilkins LM, Kaye EK, Wang HY, et al. Influence of obesity on periodontitis progression is conditional on interleukin-1 inflammatory genetic variation. *J Periodontol*. 2017;88(1):59-68.

26. Flores M, Glusman G, Brogaard K, Price ND, Hood L. P4 medicine: how systems medicine will transform the healthcare sector and society. *Per Med*. 2013;10(6):565-576.

27. Hood L. Systems biology and p4 medicine: past, present, and future. *Rambam Maimonides Med J*. 2013;4(2):e0012.

28. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. *Nat Rev Clin Oncol*. 2011;8(3):184-187.

29. Taylor AD, Micheel CM, Anderson IA, Levy MA, Lovly CM. The path(way) less traveled: a pathway-oriented approach to providing information about precision cancer medicine on my cancer genome. *Transl Oncol*. 2016;9(2):163-165.

30. Libby P. ALX-chemy: adding spice to the inflammatory soup of atherosclerosis. *Cardiovasc Res*. 2015;105(1):3-5.

31. Roca J, Vargas C, Cano I, et al. Chronic obstructive pulmonary disease heterogeneity: challenges for health risk assessment, stratification and management. *J Transl Med*. 2014;12(Suppl 2):S3.

32. Yan X, Liang A, Gomez J, Cohn L, Zhao H, Chupp GL. A novel pathway-based distance score enhances assessment of disease heterogeneity in gene expression. *BMC Bioinformatics*. 2017;18(1):309.

33. Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. *Nat Med*. 2015;21(7):730-738.

34. da Silva MK, de Carvalho ACG, Alves EHP, da Silva FRP, Pessoa LDS, Vasconcelos DFP. Genetic factors and the risk of periodontitis development: findings from a systematic review composed of 13 studies of meta-analysis with 71,531 participants. *Int J Dent*. 2017;2017:1914073.

35. Genco RJ, Borgnakke WS. Risk factors for periodontal disease. *Periodontol 2000*. 2013;62(1):59-94.

36. Jaedicke KM, Preshaw PM, Taylor JJ. Salivary cytokines as biomarkers of periodontal diseases. *Periodontol 2000*. 2016;70(1):164-183.

37. Knight ET, Liu J, Seymour GJ, Faggion CM Jr, Cullinan MP. Risk factors that may modify the innate and adaptive immune responses in periodontal diseases. *Periodontol 2000*. 2016;71(1):22-51.

38. Loos BG, Papantonopoulos G, Jepsen S, Laine ML. What is the contribution of genetics to periodontal risk? *Dent Clin North Am*. 2015;59(4):761-780.

39. Wang CJ, McCauley LK. Osteoporosis and periodontitis. *Curr Osteoporos Rep*. 2016;14(6):284-291.

40. Acharya CR, Hsu DS, Anders CK, et al. Retraction: gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587. *J Am Med Assoc* 2012: **307**: 453.

41. Io M. *Evolution of Translational Omics: Lessons Learned and the Path Forward*. Washington, DC: The National Academies Press; 2012:354.

42. Nunn ME. Understanding the etiology of periodontitis: an overview of periodontal risk factors. *Periodontol 2000*. 2003;32:11-23.

43. Hill AB. The environment and disease: association or causation? *Proc R Soc Med*. 1965;58(5):295-300.

44. Lang NP, Joss A, Orsanic T, Gusberti FA, Siegrist BE. Bleeding on probing. A predictor for the progression of periodontal disease? *J Clin Periodontol*. 1986;13(6):590-596.

45. Lang NP, Joss A, Tonetti MS. Monitoring disease during supportive periodontal treatment by bleeding on probing. *Periodontol 2000*. 1996;12:44-48.

46. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. *PLoS Genet*. 2009;5(2):e1000337.

47. Lo A, Chernoff H, Zheng T, Lo SH. Why significant variables aren't automatically good predictors. *Proc Natl Acad Sci U S A*. 2015;112(45):13892-13897.

48. Garcia RI, Compton R, Dietrich T. Risk assessment and periodontal prevention in primary care. *Periodontol 2000*. 2016;71(1):10-21.

49. Garcia RI, Nunn ME, Dietrich T. Risk calculation and periodontal outcomes. *Periodontol 2000*. 2009;50(1):65-77.

50. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359(21):2195-2207.

51. Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. *Lancet*. 2016;388(10057):2239-2253.

52. Grossi SG, Skrepcinski FB, DeCaro T, Zambon JJ, Cummins D, Genco RJ. Response to periodontal therapy in diabetics and smokers. *J Periodontol*. 1996;67(10 Suppl):1094-1102.

53. Offenbacher S, Beck JD, Moss K, et al. Results from the Periodontitis and Vascular Events (PAVE) Study: a pilot multicentered, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease. *J Periodontol*. 2009;80(2):190-201.

54. Suvan J, Petrie A, Moles DR, et al. Body mass index as a predictive factor of periodontal therapy outcomes. *J Dent Res*. 2014;93(1):49-54.

55. Patterson SD, Cohen N, Karnoub M, et al. Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. *Pharmacogenomics*. 2011;12(7):939-951.

56. Sebastiani P, Sun FX, Andersen SL, et al. Families enriched for exceptional longevity also have Increased Health-Span: Findings from the Long Life Family Study. *Front Public Health*. 2013;1:38.

57. Meisel P, Siegemund A, Grimm R, et al. The interleukin-1 polymorphism, smoking, and the risk of periodontal disease in the population-based SHIP study. *J Dent Res*. 2003;82(3):189-193.

58. Pink C, Kocher T, Meisel P, et al. Longitudinal effects of systemic inflammation markers on periodontitis. *J Clin Periodontol*. 2015;42(11):988-997.

59. Struch F, Dau M, Schwahn C, Biffar R, Kocher T, Meisel P. Interleukin-1 gene polymorphism, diabetes, and periodontitis: results from the Study of Health in Pomerania (SHIP). *J Periodontol*. 2008;79(3):501-507.

60. Kao RT, Nares S, Reynolds MA. Periodontal regeneration - intrabony defects: a systematic review from the AAP Regeneration Workshop. *J Periodontol*. 2015;86(2 Suppl):S77-S104.

61. Nevins M, Kao RT, McGuire MK, et al. Platelet-derived growth factor promotes periodontal regeneration in localized osseous defects: 36-month extension results from a randomized, controlled, double-masked clinical trial. *J Periodontol*. 2013;84(4):456-464.

62. Corella D, Carrasco P, Sorli JV, et al. Mediterranean diet reduces the adverse effect of the TCF7L2-rs7903146 polymorphism on cardiovascular risk factors and stroke incidence: a randomized controlled trial in a high-cardiovascular-risk population. *Diabetes Care*. 2013;36(11):3803-3811.

63. Chen CH, Lee CS, Lee MT, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. *N Engl J Med*. 2014;370(2):119-128.

64. Cui J, Stahl EA, Saevarsdottir S, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. *PLoS Genet*. 2013;9(3):e1003394.

65. Bergstrom J, Eliasson S, Dock J. A 10-year prospective study of tobacco smoking and periodontal health. *J Periodontol*. 2000;71(8):1338-1347.

66. Faddy MJ, Cullinan MP, Palmer JE, Westerman B, Seymour GJ. Ante-dependence modeling in a longitudinal study of periodontal disease: the effect of age, gender, and smoking status. *J Periodontol*. 2000;71(3):454-459.

67. Jansson L, Lavstedt S. Influence of smoking on marginal bone loss and tooth loss—a prospective study over 20 years. *J Clin Periodontol*. 2002;29(8):750-756.

68. Meisel P, Siegemund A, Dombrowa S, Sawaf H, Fanghaenel J, Kocher T. Smoking and polymorphisms of the interleukin-1 gene cluster (IL-1alpha, IL-1beta, and IL-1RN) in patients with periodontal disease. *J Periodontol*. 2002;73(1):27-32.

69. Tsimikas S, Duff GW, Berger PB, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). *J Am Coll Cardiol*. 2014;63(17):1724-1734.

70. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P, Group CHDRP. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA*. 2001;286(2):180-187.

71. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. *J Am Coll Cardiol*. 2017;69(6):692-711.

72. Lang NP, Suvan JE, Tonetti MS. Risk factor assessment tools for the prevention of periodontitis progression a systematic review. *J Clin Periodontol*. 2015;42(Suppl 16):S59-S70.

73. Cook NR, Paynter NP, Eaton CB, et al. Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. *Circulation*. 2012;125(14):1748-56, S1-11.

74. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. *Ann Intern Med*. 2009;150(11):795-802.

75. Paynter NP, Chasman DI, Buring JE, Shiffman D, Cook NR, Ridker PM. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. *Ann Intern Med*. 2009;150(2):65-72.

76. Heasman PA, Collins JG, Offenbacher S. Changes in crevicular fluid levels of interleukin-1 beta, leukotriene B4, prostaglandin E2, thromboxane B2 and tumour necrosis factor alpha in experimental gingivitis in humans. *J Periodontal Res*. 1993;28(4):241-247.

77. Morelli T, Moss KL, Beck J, et al. Derivation and validation of the periodontal and tooth profile classification system for patient stratification. *J Periodontol*. 2017;88(2):153-165.

78. Offenbacher S, Barros S, Champagne CM, et al. Diagnosis of periodontal disease at the periodontal tissue-biofilm interface: biological correlates. *Oral Bioscience Medicine*. 2005;213:215-220.

79. Offenbacher S, Barros SP, Singer RE, Moss K, Williams RC, Beck JD. Periodontal disease at the biofilm-gingival interface. *J Periodontol*. 2007;78(10):1911-1925.

80. Offenbacher S, Divaris K, Barros SP, et al. Genome-wide association study of biologically informed periodontal complex traits offers novel insights into the genetic basis of periodontal disease. *Hum Mol Genet*. 2016;25(10):2113-2129.

81. Axelsson P, Lindhe J. Effect of controlled oral hygiene procedures on caries and periodontal disease in adults. Results after 6 years. *J Clin Periodontol*. 1981;8(3):239-248.

82. Axelsson P, Lindhe J. The significance of maintenance care in the treatment of periodontal disease. *J Clin Periodontol*. 1981;8(4):281-294.

83. Axelsson P, Nystrom B, Lindhe J. The long-term effect of a plaque control program on tooth mortality, caries and periodontal disease in adults. Results after 30 years of maintenance. *J Clin Periodontol*. 2004;31(9):749-757.

84. Knowles JW, Burgett FG, Nissle RR, Shick RA, Morrison EC, Ramfjord SP. Results of periodontal treatment related to pocket depth and attachment level. Eight years. *J Periodontol*. 1979;50(5):225-233.

85. Knowles JW, Ramfjord SP, Burgett FG, Nissle RR, Shick RA. Plaque scores related to long-term results of periodontal therapy. *J Periodontal Res*. 1972;(10):39-40.

86. Lindhe J, Nyman S. The effect of plaque control and surgical pocket elimination on the establishment and maintenance of periodontal health. A longitudinal study of periodontal therapy in cases of advanced disease. *J Clin Periodontol*. 1975;2(2):67-79.

87. Ramfjord SP, Caffesse RG, Morrison EC, et al. 4 modalities of periodontal treatment compared over 5 years. *J Clin Periodontol*. 1987;14(8):445-452.

88. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. Prevalence of periodontitis in adults in the United States: 2009 and 2010. *J Dent Res*. 2012;91(10):914-920.

89. Eke PI, Dye BA, Wei L, et al. Update on prevalence of periodontitis in adults in the United States: NHANES 2009 to 2012. *J Periodontol*. 2015;86(5):611-622.

90. Axelsson P (ed.). Role of genetic and hereditary factors. In: *Diagnosis and Risk Prediction of Periodontal Diseases*. Hanover Park, IL: Quintessence; 2002:146-163.

91. Paulander J, Wennstrom JL, Axelsson P, Lindhe J. Some risk factors for periodontal bone loss in 50-year-old individuals. A 10-year cohort study. *J Clin Periodontol*. 2004;31(7):489-496.

92. Kornman KS, Crane A, Wang HY, et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. *J Clin Periodontol*. 1997;24(1):72-77.

93. Needleman I, Suvan J, Gilthorpe MS, et al. A randomized-controlled trial of low-dose doxycycline for periodontitis in smokers. *J Clin Periodontol*. 2007;34(4):325-333.

94. Smiley CJ, Tracy SL, Abt E, et al. Systematic review and meta-analysis on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts. *J Am Dent Assoc*. 2015;146(7):508-524 e505.

95. El-Sharkawy H, Aboelsaad N, Eliwa M, et al. Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 fatty acids and low-dose aspirin. *J Periodontol*. 2010;81 (11):1635-1643.

96. Persson GR. Prevention of periodontitis and the use of a multifactorial periodontal risk assessment model. *Oral Health Prev Dent*. 2004;2(Suppl 1):329-331.

97. Borgnakke WS, Ylostalo PV, Taylor GW, Genco RJ. Effect of periodontal disease on diabetes: systematic review of epidemiologic observational evidence. *J Periodontol*. 2013;84(4 Suppl):S135-S152.

98. Chapple IL. Genco R, working group 2 of the joint EFPAAPw. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. *J Periodontol*. 2013;84(4 Suppl):S106-S112.

99. Dietrich T, Sharma P, Walter C, Weston P, Beck J. The epidemiological evidence behind the association between periodontitis and incident atherosclerotic cardiovascular disease. *J Periodontol*. 2013;84(4 Suppl):S70-S84.

100. Janket SJ, Baird AE, Chuang SK, Jones JA. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2003;95(5):559-569.

101. Yu YH, Chasman DI, Buring JE, Rose L, Ridker PM. Cardiovascular risks associated with incident and prevalent periodontal disease. *J Clin Periodontol*. 2015;42(1):21-28.

102. Harvey GP, Fitzsimmons TR, Dhamarpatni AA, Marchant C, Haynes DR, Bartold PM. Expression of peptidylarginine deiminase-2 and -4, citrullinated proteins and anti-citrullinated protein antibodies in human gingiva. *J Periodontal Res*. 2013;48(2):252-261.

103. Ide M, Papapanou PN. Epidemiology of association between maternal periodontal disease and adverse pregnancy outcomes—systematic review. *J Periodontol*. 2013;84(4-s):S181-S194.

104. Linden GJ, Lyons A, Scannapieco FA. Periodontal systemic associations: review of the evidence. *J Periodontol*. 2013;84:S8-S19.

105. Sanz M, Kornman K, Working Group 3 of the joint EFPAAPw. Periodontitis and adverse pregnancy outcomes: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. *J Periodontol*. 2013;84(4 Suppl):S164-S169.

106. Ebersole JL, Machen RL, Steffen MJ, Willmann DE. Systemic acute-phase reactants, C-reactive protein and haptoglobin, in adult periodontitis. *Clin Exp Immunol*. 1997;107(2):347-352.

107. Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden U. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. *J Periodontol*. 2000;71(10):1528-1534.

108. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. *J Clin Periodontol*. 2008;35(4):277-290.

109. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. *J Periodontol*. 2001;72(9):1221-1227.

110. Nesse W, Abbas F, van der Ploeg I, Spijkervet FK, Dijkstra PU, Vissink A. Periodontal inflamed surface area: quantifying inflammatory burden. *J Clin Periodontol*. 2008;35(8):668-673.

111. Sato M, Iwasaki M, Yoshihara A, Miyazaki H. Association between periodontitis and medical expenditure in older adults: A 33-month follow-up study. *Geriatr Gerontol Int*. 2016;16(7):856-864.

112. Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. *Circulation*. 2014;130(10):837-844.

113. Choi YH, McKeown RE, Mayer-Davis EJ, Liese AD, Song KB, Merchant AT. Serum C-reactive protein and immunoglobulin G antibodies to periodontal pathogens may be effect modifiers of periodontitis and hyperglycemia. *J Periodontol*. 2014;85(9):1172-1181.

114. Holmlund A, Lampa E, Lind L. Oral health and cardiovascular disease risk in a cohort of periodontitis patients. *Atherosclerosis*. 2017;262:101-106.

115. Han YW. *Fusobacterium nucleatum*: a commensal-turned pathogen. *Curr Opin Microbiol*. 2015;23:141-147.

116. Han YW, Wang X. Mobile microbiome: oral bacteria in extra-oral infections and inflammation. *J Dent Res*. 2013;92(6):485-491.

117. Jeffcoat M, Parry S, Sammel M, Clothier B, Catlin A, Macones G. Periodontal infection and preterm birth: successful periodontal therapy reduces the risk of preterm birth. *Br J Obst Gyn*. 2011;118 (2):250-256.

118. Offenbacher S, Katz V, Fertik G, et al. Periodontal infection as a possible risk factor for preterm low birth weight. *J Periodontol*. 1996;67(10 Suppl):1103-1113.

119. Papapanou PN. Systemic effects of periodontitis: lessons learned from research on atherosclerotic vascular disease and adverse pregnancy outcomes. *Int Dent J*. 2015;65(6):283-291.

120. Kornman KS, Giannobile WV, Duff GW. Quo vadis: what is the future of periodontics? How will we get there? *Periodontol 2000*. 2017;75(1):353-371.

121. Fox CH, Jette AM, McGuire SM, Feldman HA, Douglass CW. Periodontal disease among New England elders. *J Periodontol*. 1994;65 (7):676-684.